Agios Pharmaceuticals Inc (AGIO) : Clarius Group scooped up 61,564 additional shares in Agios Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 109,230 shares of Agios Pharmaceuticals Inc which is valued at $7,316,225.Agios Pharmaceuticals Inc makes up approximately 3.45% of Clarius Group’s portfolio.
Other Hedge Funds, Including , Envestnet Asset Management Inc sold out all of its stake in AGIO during the most recent quarter. The investment firm sold 2,542 shares of AGIO which is valued $170,263. Columbus Circle Investors added AGIO to its portfolio by purchasing 302,889 company shares during the most recent quarter which is valued at $19,315,232. Agios Pharmaceuticals Inc makes up approx 0.22% of Columbus Circle Investors’s portfolio. Aperio Group sold out all of its stake in AGIO during the most recent quarter. The investment firm sold 5,572 shares of AGIO which is valued $256,869.Ftb Advisors reduced its stake in AGIO by selling 3 shares or 5.08% in the most recent quarter. The Hedge Fund company now holds 56 shares of AGIO which is valued at $2,679. Hamilton Lane Advisors added AGIO to its portfolio by purchasing 19,280 company shares during the most recent quarter which is valued at $949,733. Agios Pharmaceuticals Inc makes up approx 0.49% of Hamilton Lane Advisors’s portfolio.
Agios Pharmaceuticals Inc closed down -0.27 points or -0.43% at $62.54 with 4,09,422 shares getting traded on Monday. Post opening the session at $62.72, the shares hit an intraday low of $62.07 and an intraday high of $63.55 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Agios Pharmaceuticals Inc reported $-1.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $-1.51. The company had revenue of $8.98 million for the quarter, compared to analysts expectations of $8.64 million. The company’s revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.07 EPS.
Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Needham Initiated Agios Pharmaceuticals Inc on Oct 24, 2016 to “Buy”, Price Target of the shares are set at $60.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.